Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 16/20 | 0.63 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19939765 | 1.00 | SELE (0.63) | SELESELLSELPMAPK1 | |
| SCHEMBL19939763 | 0.92 | SELE (0.59) | SELESELLSELP | |
| SCHEMBL16659823 | 0.92 | SELE (0.59) | SELESELLSELP | |
| SCHEMBL16659816 | 0.91 | SELE (0.64) | SELESELLSELP | |
| SCHEMBL18026351 | 0.91 | SELE (0.64) | SELESELLSELP | |
| SCHEMBL17877663 | 0.91 | SELE (0.57) | SELESELLSELP | |
| SCHEMBL16661869 | 0.87 | SELE (0.55) | SELESELLSELP | |
| SCHEMBL17881676 | 0.87 | SELE (0.55) | SELESELLSELP | |
| SCHEMBL17881708 | 0.87 | SELE (0.55) | SELESELLSELP | |
| SCHEMBL18027947 | 0.87 | SELE (0.55) | SELESELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867841-B2 | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells | GLYCOMIMETICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9796745-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160145290-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9109002-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145290-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885SELL 4/4885SELP 3/4885 |
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885SELL 4/4885SELP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.